Automated Suturing Devices Market By Product Type (Endoscopic Suturing Systems, Laparoscopic Suturing Devices, Automated Suture Fastening and Knotting Devices, Robotic-Assisted Suturing Devices); By Application (Bariatric and Metabolic Surgery, Gastrointestinal Defect Closure, Cardiovascular Surgery, General Surgery, Gynecological Surgery, Colorectal Surgery); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Endoscopy Centers and Clinics); By Usability (Single-Use/Disposable Devices, Reusable Devices); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Automated Suturing Devices Market: Reimbursement and Single-Use Systems Expand Procedure-Based Revenue

The Global Automated Suturing Devices Market was valued at USD 1.55 billion in 2025 and is projected to reach USD 2.83 billion by 2032, growing at a CAGR of 8.9%, according to Strategic Market Research.

 

The automated suturing devices market is evolving from a surgical-instrument segment into a procedure-driven consumables market. Hospitals adopt these systems when limited access, reduced operating time, endoscopic closure needs or consistent suture placement justify the added cost.

 

The market includes mechanically assisted and semi-automated devices used to place sutures, transfer needles, create full-thickness tissue plications and fasten or trim sutures. These systems remain operator-controlled and require clinicians to position the device, select tissue, manage tension and actuate each stitch. Surgical staplers, conventional needle drivers, stand-alone sutures and fully autonomous robotic platforms are outside the commercial scope.

 

Recurring revenue comes from sterile suture assemblies, needle reloads, cinches, cartridges, and titanium fasteners consumed during each procedure. Medtronic’s Endo Stitch platform uses single-stitch, triple-stitch, and wound-closure reloads, while each LSI Solutions COR-KNOT Quick Load contains one sterile titanium fastener. Boston Scientific’s OverStitch NXT is supplied as a single-use system for compatible single-channel gastroscopes. These formats move supplier economics away from occasional instrument replacement and toward procedure-linked disposable sales.

 

Endoscopic Suturing Is Becoming the Main Growth Platform

Endoscopic applications offer the strongest near-term commercial expansion because suturing can convert selected procedures from open or laparoscopic surgery into interventions performed through a flexible endoscope. Boston Scientific markets OverStitch and OverStitch NXT for endoscopic sleeve gastroplasty, transoral outlet reduction, gastrointestinal defect closure, fistula and leak management, and other therapeutic endoscopy procedures. The FDA classified OverStitch NXT as an endoscopic tissue-approximation device and found it substantially equivalent in June 2023.

OverStitch NXT also addresses an important hospital-purchasing barrier. Earlier suturing configurations commonly depended on specialized dual-channel endoscopes, limiting adoption to advanced centers with compatible equipment. The NXT system works with a broader range of single-channel gastroscopes, reducing the need for additional capital equipment and allowing suppliers to approach hospitals through their existing endoscopy infrastructure. Commercial value therefore rests as much on installed-scope compatibility and procedure workflow as on the suturing mechanism itself.

Boston Scientific’s acquisition of Apollo Endosurgery in April 2023 strengthened this market transition. The deal placed OverStitch within a global endoscopy business with established hospital relationships, physician-training resources, reimbursement teams, and distribution channels. Boston Scientific described the acquisition as its entry into the endobariatric market and an expansion of its endoluminal surgery portfolio. Smaller automated suturing developers now compete not only against the product itself but also against a large commercial platform capable of bundling closure, imaging, access, and therapeutic endoscopy technologies.

 

Obesity Creates a Large Clinical Pool but a Selective Device Market

Obesity prevalence materially overstates the addressable procedure pool. More than 890 million adults worldwide were living with obesity in 2022, while 40.3% of U.S. adults aged 20 and older had obesity during August 2021–August 2023. Only a small proportion will meet procedural criteria, receive specialist referrals, obtain insurance approval, and choose endoscopic sleeve gastroplasty or bariatric surgery.

Procedure data provide a more useful commercial measure. The American Society for Metabolic and Bariatric Surgery estimated 4,587 U.S. endoscopic sleeve gastroplasty procedures in 2023, almost unchanged from 4,600 in 2022 but more than double the 2,220 estimated in 2021. Total U.S. metabolic and bariatric procedures reached 270,089 in 2023. ESG remained a small part of that total, but each ESG directly consumes an endoscopic suturing system and multiple disposable components, making it more relevant to suppliers than the much larger pool of operations performed mainly with staplers and conventional closure methods.

Boston Scientific reported 25,000 cumulative ESG procedures worldwide through February 2024. That figure is not annual market volume and does not disclose the number of sutures used per case, but it confirms that endobariatric suturing has moved beyond isolated academic use. No credible public source reports audited total U.S. or global automated suturing device unit sales, making procedure counts and manufacturer-reported utilization the most defensible demand indicators.

 

GLP-1 Medicines Are Reshaping the Patient Funnel

GLP-1 medicines are changing the patient pathway rather than eliminating procedural demand. New ASMBS research reported that procedures captured at accredited U.S. bariatric centers fell from 217,387 in 2023 to 177,297 in 2024, a decline of more than 20%. A separate analysis of nearly 20 million patients with severe obesity found that GLP-1 prescriptions increased from fewer than 4,600 in 2018 to more than 1.4 million in 2025, while bariatric surgery use declined after 2023.

Rising obesity prevalence will not translate directly into higher endoscopic sleeve gastroplasty volumes. Adoption depends on ESG’s position between anti-obesity medication and bariatric surgery. The procedure is most relevant for patients seeking an incisionless treatment, those with inadequate response to conservative therapy, non-surgical candidates and selected revision cases. ESG may also be combined with anti-obesity medication.

 

Coding and Coverage Improve the U.S. Revenue Model

The permanent Category I CPT code 43889 became effective on January 1, 2026, for endoscopic sleeve gastroplasty. A dedicated code gives hospitals and physicians a standardized basis for billing, prior authorization, payer contracting, and claims analysis. Before the code, inconsistent billing pathways made it harder for providers to establish predictable program economics and restricted many ESG procedures to self-pay patients.

Professional recognition also improved in 2025. ASMBS added ESG to its list of endorsed endoscopic procedures, identifying it as an evidence-based option within the obesity-treatment continuum. Boston Scientific also reported that the OverStitch-based ESG procedure gained U.S. reimbursement coverage during 2025. The endobariatric business can now sell against a stronger combination of regulatory authorization, professional endorsement, procedure coding, and emerging payer coverage.

Reimbursement varies by insurer and policy despite the new CPT code, and payer approval can still depend on plan design, medical-necessity criteria, prior authorization, or state-specific rules. Growth will therefore concentrate first in integrated health systems and endoscopy programs that can document patient selection, negotiate coverage, and maintain enough case volume to support physician training and disposable inventory.

 

Gastrointestinal Closure Adds a Higher-Acuity Revenue Stream

Automated endoscopic suturing is not limited to weight-loss procedures. OverStitch systems are also used for selected gastrointestinal perforations, post-resection defects, fistulas, leaks, and stent fixation. These indications involve smaller patient populations than obesity, but they often arise in tertiary hospitals where clinicians need a secure closure option that may avoid surgical rescue, prolonged hospitalization, or additional intervention.

This segment is commercially valuable because hospitals buy closure capability rather than a single procedure. A center may use the same suturing platform for ESG, bariatric revision, defect closure, fistula management, or complication control. Broader utilization improves the economics of training, stocking, and service support. Suppliers with products that fit existing endoscopes and cover several approved indications are better positioned than systems dependent on one narrow procedure.

 

Cardiac Fasteners Provide the Strongest Evidence of Established Scale

Cardiovascular surgery represents a more mature automated suture-fastening segment. LSI Solutions’ COR-KNOT device crimps a titanium fastener onto suture and trims the remaining tails, replacing manual knot tying during selected valve repair and replacement procedures. The company states that more than 20 million fasteners have been used in more than 2 million cardiovascular patients across 91 countries over 14 years. Although the claim is manufacturer-reported and does not disclose annual sales or country-level volume, it is the clearest public indication of large-scale physical consumption within the market.

The COR-KNOT business model is strongly procedure-driven because every Quick Load contains one fastener and a valve operation may require multiple fasteners. Hospitals evaluate the system against operating-room time, aortic cross-clamp time, access through small incisions, and the consistency of suture securing. The device supports account adoption, while sterile fasteners generate recurring revenue.

Transcatheter valve replacement limits part of the cardiac opportunity. U.S. procedural data recorded 98,504 transcatheter aortic valve replacements compared with 17,568 isolated surgical aortic valve replacements in 2022. TAVR generally bypasses the surgical suturing steps that create demand for automated fasteners. Cardiac suppliers therefore have stronger exposure to minimally invasive surgical valve repair, mitral and tricuspid procedures, complex surgical replacement, and cases in which open surgery remains preferred.

Operator technique remains commercially important. FDA adverse-event reports discuss rare leaflet injury associated with improperly oriented COR-KNOT fasteners or suture tails. These reports do not establish broad product failure, but they reinforce the need for physician training, correct orientation, and procedural discipline. Hospitals assessing automated fastening systems will consider both time savings and the quality of clinical support supplied by the manufacturer.

 

Product and End-User Revenue Structure

Disposable and single-use components provide the most attractive revenue structure. Endo Stitch reloads, OverStitch suture-and-cinch components, single-use OverStitch NXT systems, and COR-KNOT Quick Loads create repeat demand every time a procedure is performed. Reusable handpieces and delivery devices remain important for account placement, but they do not reflect the full economic value of an installed hospital customer.

Endoscopic suturing is positioned to contribute the strongest incremental demand because it serves ESG, bariatric revision, and gastrointestinal closure through a common therapeutic-endoscopy channel. Automated cardiac fasteners represent the most established utilization base. General laparoscopic and gynecologic suturing remains relevant, but public procedure data do not distinguish automated-device use from manual suturing, stapling, barbed sutures, or robotic needle driving.

Hospitals will remain the principal end users because cardiac surgery, complex gastrointestinal closure, and many bariatric procedures require operating rooms, anesthesia, imaging, and complication-management capability. Hospital outpatient departments and specialized endoscopy centers are gaining importance for ESG. Ambulatory expansion will depend on payer coverage, anesthesia arrangements, trained specialists, and the center’s ability to manage adverse events or transfer patients when necessary.

 

Competitive and Commercial Outlook

Boston Scientific holds the broadest position in flexible endoscopic suturing through OverStitch and OverStitch NXT, supported by the former Apollo Endosurgery portfolio, global endoscopy distribution, reimbursement resources, and a wider gastrointestinal product range. The single-channel NXT format gives the company an opportunity to reach facilities that previously lacked dedicated dual-channel equipment.

Medtronic competes through the established Endo Stitch platform, which places interrupted or running stitches in soft tissue and supports recurring reload sales. Its strength lies in broad surgical relationships and use across minimally invasive procedures rather than a concentrated endobariatric franchise.

LSI Solutions occupies a differentiated cardiovascular position with COR-KNOT and also markets automated suturing products for laparoscopic applications. Its reported fastener utilization provides strong evidence of an established installed-user base, although the private company does not disclose revenue, annual unit shipments, or geographic sales mix.

Competition also comes from manual suturing, clips, tacking systems, staplers, barbed sutures, robotic instruments, and procedures that remove the need for surgical suturing altogether. Suppliers will gain accounts when the device reduces a difficult operative step, fits existing equipment, supports several procedures, and generates a reimbursement or efficiency benefit large enough to offset disposable cost.

 

Regional Outlook

North America is the most commercially mature region based on FDA-cleared systems, established U.S. suppliers, ESG procedure tracking, professional endorsement, and the introduction of a permanent CPT code. Reimbursement is improving but remains plan-specific, creating uneven adoption between large integrated systems and smaller centers.

Europe has an established base of advanced endoscopy and minimally invasive cardiac surgery, while COR-KNOT’s international footprint and Boston Scientific’s European OverStitch NXT offering confirm active commercial distribution. Asia-Pacific offers a large long-term surgical and obesity-treatment pool, but category-specific procedure volumes and automated suturing penetration are not publicly disclosed. Growth outside the United States will depend on specialist training, private-pay endobariatric programs, hospital budgets, distributor support, and local payment systems rather than epidemiology alone.

 

Market Outlook

Automated suturing devices will remain a specialized part of the wider wound-closure and minimally invasive surgery industry rather than replacing manual suturing across all procedures. Revenue expansion will come from procedures where access is difficult, closure quality affects whether surgery can be avoided, or faster suture fastening improves operating-room economics.

Endoscopic sleeve gastroplasty has the clearest path to incremental demand following FDA-cleared product development, ASMBS endorsement, reimbursement gains, and the 2026 CPT code. GLP-1 adoption introduces competition for patient referrals but also increases discussion of obesity treatment and may create combination or sequential treatment pathways. Gastrointestinal defect closure broadens device utilization within advanced endoscopy centers, while cardiac fasteners continue to generate substantial recurring demand from surgical valve procedures.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.55 Billion
Revenue Forecast in 2032	USD 2.83 Billion
Overall Growth Rate	CAGR of 8.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Usability, By Geography
By Product Type	Endoscopic Suturing Systems, Laparoscopic Suturing Devices, Automated Suture Fastening and Knotting Devices, Robotic-Assisted Suturing Devices
By Application	Bariatric and Metabolic Surgery, Gastrointestinal Defect Closure, Cardiovascular Surgery, General Surgery, Gynecological Surgery, Colorectal Surgery
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Endoscopy Centers and Clinics
By Usability	Single-Use/Disposable Devices, Reusable Devices
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising volume of minimally invasive and robotic-assisted surgeries; increasing demand for consistent suturing and knot-tying in complex procedures; wider adoption of endoscopic defect-closure techniques; growing preference for disposable devices that support workflow efficiency and infection-control protocols
Customization Option	Available upon request